biosurfit press / news

Find out more about the latest news and updates of biosurfit.

biosurfit featured on BBC News

Read the full article by clicking here:

 

http://www.bbc.com/news/business-29470314

biosurfit will be present at MEDICA 2014 in Dusseldorf

We will be located at Hall 2 – B 20, and we would like to invite you to visit us.

 

http://www.medica.de/exh_r/medcom2014/e/2392420

 

You will be able to learn more about our available CRP and Blood Count test an find ou more on our product pipeline tests for the next year: Inflammation and HbA1c.

 

If you would like to have a meeting, please feel free to schedule an appointment with us, through the following contacts:

 

Daniel Neves, CMO of biosurfit, tel: +351 218860169 – sales@biosurfit.com

biosurfit will be present at MEDICA 2013 in Dusseldorf (20th-24th of November)

We are pleased to annouce that biosurfit is going to be present at MEDICA Trade Fair, on the 20th to the 24th of November.

 

MEDICA is the world’s largest medical fair and as exhibitor, biosurfit is intended show to visitors from all over the world, our innovator and multi-parameter Point of care, the spinit®.

 

We will be located at Hall 2 – Both 22, and we would like to invite you to visit us at our booth and be informed of the available CRP – Protein C reative test and the Blood COunt test to be launched by the end of the year.

biosurfit is already at MEDICA 2013 online with a showrrom, accessible through the following link:

 

http://www.medica.de/exh_r/medcom2013/e/2357864

biosurfit wins the “Startup of the Year Award” from Portugal Ventures

Lisbon, 12th September 2013 – biosurfit, a rapidly-growing company focused on the Point of Care medical diagnostic market, is pleased to announce today it has won the “startup of the Year” Award from Portugal Ventures.

 

Based on their analysis of the startups operating in Portugal, Portugal Ventures recognized biosurfit with the “2013 Startup of the Year Award” for demonstrating an outstanding achievement and superior performance in areas such as leadership, business vision and execution, determination, resilience, talent, innovation and knowledge.

 

João Garcia da Fonseca, CEO of biosurfit commented: “We are delighted to receive this award from Portugal Ventures. Portugal Ventures has been investing in biosurfit since its yearly stages and it has been of a huge value to our company not only through their direct investment but specially due to the tremendous guidance, support and coaching given to the team. This award gives us even more confidence that we are on the right track but gives also even more responsibility while moving forward.”

 

About biosurfit
biosurfit is a Venture Capital backed diagnostics company founded in 2006. The company invented and developed breakthrough technologies that enable fast, precise and affordable blood analysis, aiming for the key parameters that doctors really want. These proprietary technologies are combined in the spinit® instrument, using a user-friendly reader and disposable disk cartridges for specific clinical conditions. The spinit® instrument uses only one drop of blood to deliver precise results within 10-15 minutes. Initial disposable cartridges to be launched include CRP, Blood Count and an Inflammation Panel. It is planned that future tests will include diabetes and cardiac multi-parameter panels.

 

About Portugal Ventures
Portugal Ventures is a leading Portuguese Venture Capital firm, managing several Venture Capital & Private Equity funds with a total capital of around €600 million. Portugal Ventures portfolio is made up of approximately 180 companies from a number of different industries.

 

For more Information, please contact:

 

João Garcia da Fonseca, CEO of biosurfit, tel: +351 218860169

Appointment of Dr. Ian Gilham as Chairman of the Board

biosurfit, a rapidly-growing company focused on the Point of Care medical diagnostic market, is pleased to announce today the appointment of Dr. Ian Gilham as Chairman of the Board.

 

Previously, Dr. Ian Gilham was Chief Executive Officer of Axis-Shield plc, the in-vitro diagnostics company acquired by Alere in November 2011 for £235M. Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008. Prior to its sale to Alere, Axis-Shield’s revenues rose above £100M and the company issued a maiden dividend. Before joining Axis-Shield, Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the delivery of pharmacogentic tests, as well as novel diagnostic tests used in targeting GSK’s medicines. Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics.

 

Commenting on his appointment, Dr. Ian Gilham, said: “I am delighted to join biosurfit as Chairman of the Board. It is an incredibly exciting time for the company with new opportunities ahead and a chance to support an entrepreneurial team that have developed innovative and potentially game changing technologies into a great new product. biosurfit has a tremendous potential in Point of Care Diagnostics with its spinit® instrument that is due to be launched in 2013. I look forward to working with the team to help biosurfit in reaching its great ambitions.”

 

João Garcia da Fonseca, Founder and CEO of biosurfit, commented: “We are all delighted to have Ian join the team, particularly as we are preparing to launch our spinit® instrument in the Point of Care testing market. Ian is an experienced leader with an international track record in the research, development and commercialization of diagnostic and pharmaceutical products. His wealth of experience and great knowledge of the IVD industry will be extremely valuable to biosurfit.”

 

About biosurfit
biosurfit is a Venture Capital backed diagnostics company founded in 2006. The company invented and developed breakthrough technologies that enable fast, precise and affordable blood analysis, aiming for the key parameters that doctors really want. These proprietary technologies are combined in the spinit® instrument, using a user-friendly reader and disposable disk cartridges for specific clinical conditions. The spinit® instrument uses only one drop of blood to deliver precise results within 10-15 minutes. Initial disposable cartridges to be launched in 2013 include CRP, Blood Count and an Inflammation Panel. It is planned that future tests will include diabetes and cardiac multi-parameter panels.

 

For more information, please contact:

 

João Garcia da Fonseca, CEO of biosurfit, tel: +351 217500228
Mary-Jane Elliott or Claire Dickinson, M:Communications, tel: +44 (0) 20 7920 2345